127 related articles for article (PubMed ID: 10428398)
1. Novel vasopressin V2 receptor-selective antagonists, pyrrolo[2,1-a]quinoxaline and pyrrolo[2,1-c][1,4]benzodiazepine derivatives.
Ohtake Y; Naito A; Hasegawa H; Kawano K; Morizono D; Taniguchi M; Tanaka Y; Matsukawa H; Naito K; Oguma T; Ezure Y; Tsuriya Y
Bioorg Med Chem; 1999 Jun; 7(6):1247-54. PubMed ID: 10428398
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.
Naito A; Ohtake Y; Hasegaw H; Fukaya AY; Kurasawa T; Naito K; Matsukawa H; Oguma T; Ezure Y; Tsuriya Y; Tanaka H; Koike K; Shigenobu K
Biol Pharm Bull; 2000 Feb; 23(2):182-9. PubMed ID: 10706381
[TBL] [Abstract][Full Text] [Related]
3. Histopathological study of kidney abnormalities in an experimental SIADH rat model and its application to the evaluation of the pharmacologic profile of VP-343, a selective vasopressin V2 receptor antagonist.
Naito A; Hasegawa H; Kurasawa T; Ohtake Y; Matsukawa H; Ezure Y; Koike K; Shigenobu K
Biol Pharm Bull; 2001 Aug; 24(8):897-901. PubMed ID: 11510481
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic efficacy of VP-343, a selective vasopressin V2 receptor antagonist, in the experimental SIADH rat model.
Naito A; Hasegawa H; Kurasawa T; Ohtake Y; Matsukawa H; Ezure Y; Tsuriya Y; Koike K; Shigenobu K
Biol Pharm Bull; 2000 Nov; 23(11):1323-7. PubMed ID: 11085360
[TBL] [Abstract][Full Text] [Related]
5. 5-fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-yl carbonyl)-2-pyridinyl]benzamide (CL-385004) and analogs as orally active arginine vasopressin receptor antagonists.
Aranapakam V; Albright JD; Grosu GT; Delos Santos EG; Chan PS; Coupet J; Ru X; Saunders T; Mazandarani H
Bioorg Med Chem Lett; 1999 Jul; 9(13):1737-40. PubMed ID: 10406633
[TBL] [Abstract][Full Text] [Related]
6. (4-Substituted-phenyl)-(5H-10,11-dihydro-pyrrolo [2,1-c][1,4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators.
Venkatesan AM; Grosu GT; Failli AA; Chan PS; Coupet J; Saunders T; Mazandarani H; Ru X
Bioorg Med Chem Lett; 2005 Nov; 15(22):5003-6. PubMed ID: 16153837
[TBL] [Abstract][Full Text] [Related]
7. Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-y l)carbonyl]-2-phenylbenzanilide derivatives.
Shimada Y; Taniguchi N; Matsuhisa A; Sakamoto K; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1644-51. PubMed ID: 11086891
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydropyrrolo[1,2-a]quinoxalines and tetrahydropyrrolo[1,2-a]pyrido[3,2-a]pyrazines: vascular smooth muscle relaxants and antihypertensive agents.
Abou-Gharbia M; Freed ME; McCaully RJ; Silver PJ; Wendt RL
J Med Chem; 1984 Dec; 27(12):1743-6. PubMed ID: 6502606
[TBL] [Abstract][Full Text] [Related]
9. Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.
Matthews JM; Hoekstra WJ; Dyatkin AB; Hecker LR; Hlasta DJ; Poulter BL; Andrade-Gordon P; de Garavilla L; Demarest KT; Ericson E; Gunnet JW; Hageman W; Look R; Moore JB; Reynolds CH; Maryanoff BE
Bioorg Med Chem Lett; 2004 Jun; 14(11):2747-52. PubMed ID: 15125926
[TBL] [Abstract][Full Text] [Related]
10. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide derivatives.
Matsuhisa A; Koshio H; Sakamoto K; Taniguchi N; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 1998 Oct; 46(10):1566-79. PubMed ID: 9810694
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
[TBL] [Abstract][Full Text] [Related]
12. The design, synthesis and physical chemical properties of novel human vasopressin V2-receptor antagonists optimized for parenteral delivery.
Ashwell MA; Bagli JF; Caggiano TJ; Chan PS; Molinari AJ; Palka C; Park CH; Rogers JF; Sherman M; Trybulski EJ; Williams DK
Bioorg Med Chem Lett; 2000 Apr; 10(8):783-6. PubMed ID: 10782686
[TBL] [Abstract][Full Text] [Related]
13. Tricyclic quinoxalinediones: 5,6-dihydro-1H-pyrrolo[1,2,3-de] quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de] quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor.
Nagata R; Tanno N; Kodo T; Ae N; Yamaguchi H; Nishimura T; Antoku F; Tatsuno T; Kato T; Tanaka Y
J Med Chem; 1994 Nov; 37(23):3956-68. PubMed ID: 7966156
[TBL] [Abstract][Full Text] [Related]
14. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives.
Matsuhisa A; Tanaka A; Kikuchi K; Shimada Y; Yatsu T; Yanagisawa I
Chem Pharm Bull (Tokyo); 1997 Nov; 45(11):1870-4. PubMed ID: 9396163
[TBL] [Abstract][Full Text] [Related]
15. Quinoxaline chemistry. Part 16. 4-substituted anilino and 4-substituted phenoxymethyl pyrrolo[1,2-a]quinoxalines and N-[4-(pyrrolo[1,2-a]quinoxalin-4-yl)amino and hydroxymethyl]benzoyl glutamates. Synthesis and evaluation of in vitro biological activity.
Alleca S; Corona P; Loriga M; Paglietti G; Loddo R; Mascia V; Busonera B; La Colla P
Farmaco; 2003 Sep; 58(9):639-50. PubMed ID: 13679156
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.
Matsuhisa A; Taniguchi N; Koshio H; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):21-31. PubMed ID: 10705470
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist.
Tsukada J; Tahara A; Tomura Y; Wada Ki; Kusayama T; Ishii N; Aoki M; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Eur J Pharmacol; 2002 Jun; 446(1-3):129-38. PubMed ID: 12098594
[TBL] [Abstract][Full Text] [Related]
18. New ferrocenic pyrrolo[1,2-a]quinoxaline derivatives: synthesis, and in vitro antimalarial activity.
Guillon J; Moreau S; Mouray E; Sinou V; Forfar I; Fabre SB; Desplat V; Millet P; Parzy D; Jarry C; Grellier P
Bioorg Med Chem; 2008 Oct; 16(20):9133-44. PubMed ID: 18819813
[TBL] [Abstract][Full Text] [Related]
19. Potent platelet-derived growth factor-beta receptor (PDGF-betaR) inhibitors: Synthesis and structure-activity relationships of 7-[3-(cyclohexylmethyl)ureido]-3-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl}quinoxalin-2(1H)-one derivatives.
Aoki K; Obata T; Yamazaki Y; Mori Y; Hirokawa H; Koseki J; Hattori T; Niitsu K; Takeda S; Aburada M; Miyamoto K
Chem Pharm Bull (Tokyo); 2007 Feb; 55(2):255-67. PubMed ID: 17268099
[TBL] [Abstract][Full Text] [Related]
20. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
Serradeil-Le Gal C; Wagnon J; Simiand J; Griebel G; Lacour C; Guillon G; Barberis C; Brossard G; Soubrié P; Nisato D; Pascal M; Pruss R; Scatton B; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 2002 Mar; 300(3):1122-30. PubMed ID: 11861823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
